eligibility_summary
Adults 18–75 with histologically confirmed measurable cancer (solid tumors or lymphoma), MICA/B+, ECOG 0–2, life expectancy ≥3 mo, failed/unwilling for ≥3rd-line, ≥4‑wk washout, adequate labs, consent, contraception/negative pregnancy test. Exclude other recent cancers, symptomatic/unstable brain mets, active/severe autoimmune disease, immunodeficiency/HIV, active HBV/HCV, serious illness/infection, severe hypersensitivity, recent trials/cell‑gene therapy, or investigator‑assessed noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: NKG2D-CAR-NK92 cells—biological, gene‑modified, off‑the‑shelf allogeneic NK cell therapy (engineered NK‑92 cell line). Mechanism of action: The CAR uses the NKG2D recognition domain to bind stress‑induced NKG2D ligands on tumors (e.g., MICA/MICB), activating NK‑cell cytotoxicity (perforin/granzyme release and cytokine secretion) to lyse cancer cells. Targets: MICA/B‑positive solid tumor cells, the NKG2D ligand pathway on tumors, innate NK effector pathways within the engineered NK‑92 cells. Trial: Phase 1, single‑arm IV infusions (0.5–2×10^6/kg twice weekly) in relapsed/refractory solid tumors.